The Statistic That Was Signed Years Before You Enrolled: How Endpoint Negotiation Shapes a Pain Drug's Fate

When a Phase III pain trial makes headlines, the coverage usually follows a familiar script: the drug worked, or it didn't. Patients with osteoarthritis or chronic low back pain read the verdict as a statement about the molecule itself. Yet the outcome was often determined years earlier, in a quieter negotiation — one between the sponsor and the FDA over what, precisely, would count as success.

That negotiation produces the primary endpoint: the single pre-specified measure that the trial must win on, at a pre-specified time point, against a pre-specified statistical bar. Everything else in a 5,000-patient program — the secondary measures, the rescue medications, the duration of follow-up — is, from a regulatory standpoint, decoration.

Why WOMAC Carries So Much Weight

Most osteoarthritis pain trials in the United States anchor on the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), a validated questionnaire in which patients rate pain, stiffness, and physical function on a numerical scale. The pain subscale, typically averaged over a defined window rather than measured at a single visit, becomes the number on which the entire program rises or falls.

The FDA's 2018 draft guidance on osteoarthritis treatment — and its earlier effort to define what constitutes a "clinically meaningful" within-patient change — pushed sponsors toward averaging pain scores over three or more months rather than relying on a snapshot at week 16. The rationale was sound: single-visit scores are noisy and can be gamed by scheduling. But the practical effect was to raise the bar. A drug that delivers a genuine early benefit may see that benefit attenuate as placebo responses deepen and patients in both arms drift toward surgery, injections, or resignation.

The Responder Definition: Where Trials Are Won and Lost

Averaged change scores tell only half the story. Many pivotal programs also require a responder analysis: a pre-specified proportion of patients must achieve a defined threshold — for example, a 50 percent reduction in pain — in the active arm relative to placebo, with statistical significance on that binary outcome.

These definitions are not chosen by the sponsor alone. Under the FDA's end-of-Phase II meeting framework, sponsors submit a statistical analysis plan in principle, and the agency signals whether the proposed endpoint and responder threshold will support approval. Once enrollment begins, the definition is effectively locked. A trial cannot retroactively declare that a 30 percent reduction "would have been meaningful" after missing the 50 percent bar.

This is where the counterintuitive outcomes come from. Consider a molecule that produces a real, statistically significant separation from placebo on the continuous WOMAC pain scale, but where only 44 percent of treated patients cross the 50 percent responder threshold versus 41 percent on placebo — a difference that fails the significance test on the binary endpoint. By the pre-agreed rules, the trial has failed, even though the drug "worked" in a sense any clinician would recognize.

Same Molecule, Opposite Verdicts

The NGF-inhibitor saga — including the tanezumab program — illustrated this dynamic with unusual clarity. Across the Phase III osteoarthritis program, some individual trials met their primary endpoints while others in the same development plan did not, despite testing the same compound at overlapping doses. Differences in comparator arms (active comparators such as naproxen compress the placebo-drug gap), joint subpopulations, background therapy allowances, and the specific averaging windows all shifted the arithmetic.

A trial powered against an active comparator must show superiority over a drug that already works. A trial powered against placebo must overcome a placebo response that in US osteoarthritis studies has climbed steadily over two decades — in some recent programs exceeding 40 percent of the effect seen in the active arm. The molecule did not change between trials. The statistical terrain did.

What Clinicians and Advocates Should Ask

For physicians interpreting trial headlines — and for patient advocates helping families understand them — a handful of questions cuts through the noise:

• What was the primary endpoint, and at what time point? A positive result on a secondary measure at week 6 is not a positive trial.
• Was the primary analysis a mean change score, a responder rate, or both? Read the statistical analysis plan, which is increasingly published alongside results in journals and on ClinicalTrials.gov.
• What was the comparator? Superiority over naproxen is a different claim than superiority over placebo.
• Was the trial part of a program? Regulators typically require two adequate, well-controlled studies. One win and one loss in a four-trial program tells a more complete story than either headline alone.
• Was the analysis population modified after unblinding? Post-hoc population redefinitions are a recognized red flag in FDA advisory committee reviews.

The Case for Endpoint Literacy

There is a legitimate policy debate about whether current endpoint conventions overstate the difficulty of demonstrating value in chronic pain — whether requiring a 50 percent responder threshold in a condition where patients celebrate any meaningful relief reflects the patient's reality or the statistician's convenience. The FDA's patient-focused drug development initiatives, including the 21st Century Cures Act obligations, have begun pushing toward endpoints anchored in what patients themselves consider meaningful change.

Until those frameworks mature, the burden of interpretation falls on readers. A failed trial is not always a failed drug, and a successful one is not always a clinically important one. The verdict was written into the protocol before the first patient was randomized — and the most informed readers are the ones who go back and read it.

This article is for informational purposes and does not constitute medical advice. Patients considering trial enrollment should discuss options with their treating physician and review the informed consent document and trial listing on ClinicalTrials.gov.